| 孔姝婧,侯晓阳,孙 瑶,张警兮,王枫荻,黄 炎.雷公藤多苷片联合NB-UVB对寻常型银屑病炎症水平、血脂指标及卒中风险的影响[J].现代生物医学进展英文版,2023,(6):1160-1164. |
| 雷公藤多苷片联合NB-UVB对寻常型银屑病炎症水平、血脂指标及卒中风险的影响 |
| The Effect of Tripterygium Wilfordii Polyglycoside Tablets Combined with NB-UVB on Inflammation Level, Blood Lipid Index and Stroke Risk in Patients with Psoriasis Vulgaris |
| Received:August 04, 2022 Revised:August 27, 2022 |
| DOI：10.13241/j.cnki.pmb.2023.06.032 |
| 中文关键词: 雷公藤多苷片 NB-UVB 寻常型银屑病 |
| 英文关键词: Tripterygium wilfordii polyglycoside tablets NB - UVB rays Psoriasis vulgaris |
| 基金项目:江苏省研究生创新课题（KYCX17_1715） |
|
| Hits: 894 |
| Download times: 463 |
| 中文摘要: |
| 摘要 目的：探讨雷公藤多苷片联合NB-UVB对寻常型银屑病炎症水平、血脂指标及卒中风险的影响。方法：选择2020年1月到2021年12月来我院诊治的寻常型银屑病患者72例，根据随机数字表法，将72例患者分为对照组（36例）与观察组（36例），对照组患者给予NB-UVB的全身照射治疗，观察组在对照组基础上给予雷公藤多苷片治疗，对比两组的治疗效果，对比两组患者治疗前、治疗12周时的PASI评分，对比两组患者治疗前、治疗12周的血清IL-22、IL-17、TNF-α及YKL-40水平，对比两组患者治疗前、治疗12周的血清血脂水平，对比两组患者治疗12周时的卒中风险程度，对比两组患者治疗期间的不良反应发生情况。结果：观察组有效98.33%明显较对照组86.67%高，P<0.05。治疗前，两组的PASI评分对比无差异（P>0.05）；治疗12周时，两组的PASI评分降低明显，且观察组明显较对照组低（P<0.05）。治疗前，两组的血清IL-22、IL-17、TNF-α及YKL-40水平对比无统计学意义，治疗12周时，两组的血清IL-22、IL-17、TNF-α及YKL-40水平明显降低，且观察组明显较对照组低（P<0.05）。治疗前，两组患者的血清血脂水平对比无统计学意义（P>0.05）；治疗12周后，观察组的总胆固醇、甘油三酯、低密度脂蛋白水平明显降低，高密度脂蛋白水平明显升高，且观察组与对照组对比有统计学意义（P<0.05），对照组与治疗前对比无统计学意义（P>0.05）；治疗12周时，观察组的卒中风险程度明显较对照组低（P<0.05）。治疗期间，两组患者均完成治疗，无明显不良反应。结论：与单独应用NB-UVB相比，雷公藤多苷片联合NB-UVB可降低寻常型银屑病患者的炎症水平，改善血脂指标水平，降低患者的卒中风险。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the effects of tripterygium wilfordii polyglycoside tablets combined with NB-UVB on inflammation level, blood lipid indexes and stroke risk in patients with psoriasis vulgaris. Methods: 72 patients with psoriasis vulgaris treated in our hospital from January 2020 to December 2021 were selected. According to the random number table method, 72 patients were divided into thematched group (n = 36) and observation group (n = 36). The matched group were treated with NB-UVB total body irradiation, while patients in observation group were treated with tripterygium wiltergium polyglycoside tablets on the basis of matched group. The treatment effect of the two groups was compared, the PASI score of the two groups before treatment and after treatment for 12 weeks were compared, the serum levels of IL-22, IL-17, TNF-α and YKL-40 of the two groups before treatment and after treatment for 12 weeks were compared, and the serum lipid levels of the two groups before treatment and after treatment for 12 weekswere compared. The degree of stroke risk at 12 weeks of treatment were compared between the two groups, and the incidence of adverse reactions during treatment were compared between the two groups. Results: The effectiveness of observation group 98.33% was higher than matched group 86.67% (P<0.05). Before treatment, there was no difference in PASI score between the two groups (P>0.05). After treatment for 12 weeks, the PASI score of the two groups decreased, and the observation group was lower than the matched group(P<0.05). Before treatment, there was no difference in serum levels of IL-22, IL-17, TNF-α and YKL-40 between the two groups. After treatment for 12 weeks, the serum levels of IL-22, IL-17, TNF-α and YKL-40 in the two groups were decreased, and the observation group was lower than the matched group(P<0.05). Before treatment, there was no difference in serum lipid levels between the two groups (P>0.05). After treatment for 12 weeks, the levels of total cholesterol, triglyceride and low-density lipoprotein in the observation group were decreased, while the levels of high-density lipoprotein were significantly increased, and the comparison between the observation group and the matched group was significant (P<0.05), while the comparison between the matched group and before treatment was not significant (P>0.05). After treatment for 12 weeks, the risk of stroke in the observation group was lower than matched group(P<0.05). During the treatment, both groups of patients completed the treatment without obvious adverse reactions. Conclusion: Compared with NB-UVB alone, tripterygium wilfordii polyglycoside tablets combined with NB-UVB can reduce the level of inflammation, improve the level of blood lipid, and reduce the risk of stroke in patients with psoriasis vulgaris. |
|
View Full Text
View/Add Comment Download reader |
| Close |
|
|
|
